Department of Clinical Child and Adolescent Studies, Leiden University, Leiden, the Netherlands; Leiden Institute for Brain and Cognition, Leiden University Medical Centre, Leiden, the Netherlands.
Department of Pediatrics, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, the Netherlands.
Mol Genet Metab. 2018 Sep;125(1-2):96-103. doi: 10.1016/j.ymgme.2018.07.002. Epub 2018 Jul 7.
The aim of this study was to examine Health-Related Quality of Life (HRQoL) of patients with Phenylketonuria (PKU) in three different age groups and to investigate the impact of metabolic control and tetrahydrobiopterin (BH4) treatment on HRQoL of these patients. Participants were 90 early-treated patients aged 7 to 40 years (M = 21.0, SD = 10.1) and 109 controls aged 7 to 40.8 years (M = 19.4, SD = 8.6). HRQoL was assessed with the (generic) TNO-AZL questionnaires. Overall, good HRQoL was reported for children below 12 years of age, although they were judged to be less autonomic than their healthy counterparts. Adolescents aged 12-15 years showed poorer HRQoL in the domain "cognitive functioning" compared to controls. For adults ≥16 years, poorer age-controlled HRQoL was found for the domains cognition, depressive moods, and anger, with a further trend for the domain "pain". With respect to metabolic control, only for adult PKU-patients robust associations were observed, indicating poorer functioning, most notably in the domains cognition, sleep, pain, sexuality and anger, with higher historical and concurrent Phe-levels. With respect to BH4-use, effects on HRQoL were again only observed for adult PKU-patients. After controlling for age and historical Phe-levels, small but significant differences in favor of adult BH4-users compared to non-users were observed for HRQoL-categories happiness, anger, and social functioning. Together, these results show that, particularly for adult PKU-patients, HRQoL-problems are evident and that many of these problems are related to (history of) metabolic control. Beneficial effects of BH4-use appear to be limited to those associated with relief from the practical burdens related to the strict dietary treatment regimen, i.e. general mood and sociability, whereas metabolic control is more strongly related to basic physical and cognitive functioning.
本研究旨在考察苯丙酮尿症(PKU)患者在三个不同年龄组的健康相关生活质量(HRQoL),并探讨代谢控制和四氢生物蝶呤(BH4)治疗对这些患者 HRQoL 的影响。参与者为 90 名早治疗的 7 至 40 岁患者(M=21.0,SD=10.1)和 109 名 7 至 40.8 岁的对照组(M=19.4,SD=8.6)。HRQoL 采用(通用)TNO-AZL 问卷进行评估。总体而言,12 岁以下儿童报告的 HRQoL 较好,尽管他们被认为不如健康对照组自主。12-15 岁的青少年在“认知功能”领域的 HRQoL 较对照组差。对于≥16 岁的成年人,认知、抑郁情绪和愤怒领域的年龄控制较差的 HRQoL 被发现,“疼痛”领域进一步呈趋势。关于代谢控制,只有成人 PKU 患者存在与代谢控制显著相关的关联,表明功能较差,尤其是在认知、睡眠、疼痛、性和愤怒等领域,历史和当前的 Phe 水平更高。关于 BH4 的使用,仅在成年 PKU 患者中观察到对 HRQoL 的影响。在控制年龄和历史 Phe 水平后,与非 BH4 使用者相比,成年 BH4 使用者在 HRQoL 类别(幸福、愤怒和社会功能)方面表现出较小但显著的优势。综上所述,特别是对于成年 PKU 患者,明显存在 HRQoL 问题,其中许多问题与(历史)代谢控制有关。BH4 使用的有益效果似乎仅限于与缓解严格饮食治疗方案相关的实际负担相关的一般情绪和社交能力,而代谢控制与基本的身体和认知功能更相关。